Ligand appoints Martine Zimmermann to board of directors

LIGAND PHARMACEUTICALS INC

Zimmermann appointed on Sept 22, 2023; serves as independent director.
SVP and Head of Regulatory Affairs and R&D Quality at Ipsen Biopharmaceuticals since Jan 2023.
Granted RSUs (2,285 shares) and options (11,345 shares at $59.08 strike), vesting over 3 years.
Also receives cash compensation per company's director compensation policy.
Board determined Zimmermann independent under Nasdaq rules; no material transactions with company.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Martine Zimmermann

member of Board

LGND · LIGAND PHARMACEUTICALS INC

Effective: 2023-09-22
Filed: September 27, 2023, 7:59 PM ET

On September 22, 2023, the board of directors (the “Board”) of Ligand Pharmaceuticals Incorporated (the “Company”) appointed Martine Zimmermann as a member of Board.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Martine Zimmermann was appointed as member of Board at LIGAND PHARMACEUTICALS INC.

Action: appointed
Role: member of Board

Exact text from the filing

On September 22, 2023, the board of directors (the “Board”) of Ligand Pharmaceuticals Incorporated (the “Company”) appointed Martine Zimmermann as a member of Board.

View on SEC.gov

LIGAND PHARMACEUTICALS INC filing history →

Source: SEC EDGAR

accession 0000886163-23-000071

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.